

## Nexobrid® (anacaulase-bcdb) - Expanded indication

- On August 15, 2024, <u>Vericel Corporation announced</u> the FDA approval of <u>Nexobrid (anacaulase-bcdb)</u>, for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.
  - Nexobrid was previously approved for this indication in adults only.
- The safety and effectiveness of Nexobrid have not been established for treatment of:
  - Chemical or electrical burns
  - Burns on the face, perineum, or genitalia
  - Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
  - Circumferential burns
  - Burns in patients with significant cardiopulmonary disease, including inhalation injury.
- Nexobrid is not recommended for:
  - Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance
  - Treatment of burn wounds where medical devices (eg, implants, pacemakers, shunts) or vital structures (eg, large vessels) could become exposed during eschar removal.
- The approval of Nexobrid for the expanded indication was based on an open label, randomized, controlled, two arm study comparing Nexobrid to standard of care treatment in 145 patients 7 months to 18 years of age with DPT and/or FT thermal burns.
  - The median time to ≥ 95% eschar removal was 0.99 day (95% CI: 0.88, 1.04) with Nexobrid vs. 5.99 days (95% CI: 2.71, 9.84) with standard of care.
- In pediatric patients 6 years of age and older, Nexobrid is applied as a 3 mm thick layer (approximate thickness of a tongue depressor) to a burn wound area of up to 15% body surface area (BSA) in one application. Nexobrid should be removed after 4 hours. A second application of Nexobrid is not recommended.
- In pediatric patients less than 6 years of age, Nexobrid should be applied as a 3 mm thick layer (approximate thickness of a tongue depressor) to a burn wound area of up to 10% BSA in one application. Nexobrid should be removed after 4 hours. A second application of Nexobrid is not recommended.
- Refer to the Nexobrid drug label for adult dosing.

## **Optum**

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.